Reality Check on HIV
Market access for HIV reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: A slight reduction in restrictions for commercial pharmacy benefit formularies
- Class Trends: What the 2018 trend of HIV drugs going generic means for the rest of the class
- Key Findings: Payer contracting's major role in HIV and how that's shifting in 2018
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.